Literature DB >> 11166881

Ensuring vaccine safety in immunization programmes--a WHO perspective.

L Jodar1, P Duclos, J B Milstien, E Griffiths, M T Aguado, C J Clements.   

Abstract

Ever since vaccines were firstly used against smallpox, adverse events following immunization have been reported. As immunization programmes expand to reach even the most remote communities in the poorest countries, it is likely that many more events will be temporally linked with vaccine administration. Furthermore, the profound shift in the general public and media interest in adverse events may lead to undue concerns and allegations which may ultimately jeopardize immunization programmes world-wide. While the health professional has understood this issue for some time, the public and the media have now also become all too aware of the significance of vaccine-related adverse events. The familiar vaccines, well-tested over decades, have not changed--but the perception regarding their safety has shifted. Claims outrageous or reasonable are being made against both the old and the newly-introduced vaccines. At the same time, the immunological and genetic revolution of the last decade may well bring to our notice some hypothetical risks that need to be addressed at pre-clinical level. WHO has been at the leading edge to guarantee vaccine safety for the last 30 years and will continue to do so. The Organization's plans for the next decade and beyond include the Safe Injection Global Network (SIGN), the development and introduction of safer technologies, and the prevention, early detection and management of AEFIs. The new technologies include needle-containing injection devices such as the autodisable syringe, as well as mucosal and transcutaneous immunization. Training will continue to be at the centre of WHO's efforts, limiting human error to a minimum. Mechanisms have been set in place to detect and respond to new and unforeseen events occurring. Above all, there is a willingness to respond to new climates and new technologies so that the Organization is in the best position to ensure safe immunization for all the world's children.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166881     DOI: 10.1016/s0264-410x(00)00358-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  Immunisation safety: a priority of the World Health Organization's Department of Vaccines and Biologicals.

Authors:  P Duclos; C A Hofmann
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Vaccine Presentation and Packaging Advisory Group: a forum for reaching consensus on vaccine product attributes.

Authors:  Osman David Mansoor; Debra Kristensen; Andrew Meek; Simona Zipursky; Olga Popova; Olga Popovaa; InderJit Sharma; Gisele Miranda; Jules Millogo; Heidi Lasher
Journal:  Bull World Health Organ       Date:  2012-11-05       Impact factor: 9.408

Review 3.  Cytokines: the future of intranasal vaccine adjuvants.

Authors:  Afton L Thompson; Herman F Staats
Journal:  Clin Dev Immunol       Date:  2011-07-31

4.  Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier.

Authors:  Z Q Xiang; G P Gao; A Reyes-Sandoval; Y Li; J M Wilson; H C J Ertl
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 5.  New routes for allergen immunotherapy.

Authors:  Pål Johansen; Seraina von Moos; Deepa Mohanan; Thomas M Kündig; Gabriela Senti
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

6.  Intranasal co-delivery of IL-6 gene enhances the immunogenicity of anti-caries DNA vaccine.

Authors:  Ling-kai Su; Fei Yu; Zhao-fei Li; Chang Zeng; Qing-an Xu; Ming-wen Fan
Journal:  Acta Pharmacol Sin       Date:  2014-05       Impact factor: 6.150

7.  Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits.

Authors:  Herman F Staats; Jeffrey R Fielhauer; Afton L Thompson; Alice A Tripp; Ashley E Sobel; Massimo Maddaloni; Soman N Abraham; David W Pascual
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

8.  Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable Haemophilus influenzae.

Authors:  L A Novotny; J D Clements; L O Bakaletz
Journal:  Mucosal Immunol       Date:  2011-02-16       Impact factor: 7.313

9.  Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously.

Authors:  Fernando Güereña-Burgueño; Eric R Hall; David N Taylor; Frederick J Cassels; Daniel A Scott; Marcia K Wolf; Zachary J Roberts; Galina V Nesterova; Carl R Alving; Gregory M Glenn
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

Review 10.  New directions in immunotherapy.

Authors:  Linda Cox; Enrico Compalati; Thomas Kundig; Mark Larche
Journal:  Curr Allergy Asthma Rep       Date:  2013-04       Impact factor: 4.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.